Patent intelligence · US
US 8614179
Antibacterial combination therapy for the treatment of gram positive bacterial infections
Antibacterial combination therapy for the treatment of gram positive bacterial infections
Patent details — US 8614179
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 24, 2013
- Expiration
- Dec 19, 2033
- Applicant
- E-Therapeutics PLC
- Claims
- 4
- CPC classes
- A61K, A61K31/336, A61K31/4174, A61K31/42
Quick answer
US 8614179 (Antibacterial combination therapy for the treatment of gram positive bacterial infections) is held by E-Therapeutics PLC. Status: granted. Granted Dec 24, 2013. Expires Dec 19, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- E-Therapeutics PLC
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K31/336, A61K31/4174, A61K31/42, A61K38/12, A61K38/16
More from E-Therapeutics PLC
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 8614179?
US 8614179 (Antibacterial combination therapy for the treatment of gram positive bacterial infections) is held by E-Therapeutics PLC. Status: granted. Granted Dec 24, 2013. Expires Dec 19, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8614179?
E-Therapeutics PLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 8614179 expire?
Our index shows an expiration date of Dec 19, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.